2/19/2025 6:32:40 PM The Landscape of Regeneron’s Eylea® Litigation After the Federal Circuit Affirmed Two Preliminary Injunction Orders Blocking Biosimilar Market Entry By Dan Liu A biosimilar is a biologic drug that is highly similar, but not identical, to an already approved biologic drug, i.e. the reference...
/Passle/63ef8bdcf636e911c850090e/SearchServiceImages/2025-02-19-17-39-24-838-67b6174c8e073529404d9e62.jpg)
